UK pharmaceutical and biotech companies face a structural currency profile defined by predominantly USD revenue (from US licensing deals, milestone payments, contract research, and royalty income) against a predominantly GBP and EUR cost base (UK staff, EU contract manufacturing, EU regulatory work). The mismatch is largest for clinical-stage biotechs pre-revenue from sales but already receiving USD milestone or licensing payments, and for established pharma with US partnership income lines. The combination of multi-year USD revenue contracts, dated milestone receipts, and irregular but large licensing tranches makes laddered forward contracts and multi-currency receiving accounts essential — typically saving £100,000 to £500,000 a year in FX margin and milestone-timing risk for a mid-size UK biotech.
Who this guide is for
This guide is written for finance leaders at UK pharmaceutical and biotech companies with international revenue or cost exposure. Typical readers include CFOs and finance directors at clinical-stage biotechs with US licensing income; established UK pharma firms with US partnership royalties; contract research organisations (CROs) servicing US sponsors; medical device companies with US distribution agreements; UK-based diagnostic and digital health businesses with US enterprise customers; and UK life sciences SMEs running clinical trials with US contract research providers.
Cambridge Currencies operates international business payments via our FCA-authorised partners Currencycloud (FRN 900199) and ScioPay (FRN 927951). Every transaction is completed by phone with a dedicated specialist — a model well-suited to the high-value, milestone-triggered payment flows characteristic of pharma and biotech licensing.
Why UK pharma and biotech is structurally USD-heavy
The UK life sciences sector exports approximately £25 billion annually per Association of the British Pharmaceutical Industry reporting, with the United States as the dominant single market. For UK biotech specifically — companies developing novel therapeutics, diagnostics or platform technologies — the US-revenue concentration is even more pronounced because:
- The US is the world’s largest pharmaceutical market. US drug sales represent roughly 45 percent of global pharma revenue. Any UK biotech with a successful asset is materially exposed to US commercial terms.
- FDA approval pathway dominates licensing decisions. US partnership and out-licensing deals are structured around FDA milestones — IND filing, Phase 1/2/3 starts, NDA acceptance, FDA approval, launch. Each triggers a USD-denominated milestone payment.
- Big pharma deal-making is USD-denominated. When UK biotechs license assets to Pfizer, Merck, AbbVie, BMS or any large US pharma, the deal currency is USD. Upfront, milestones, royalties — all USD.
- Contract research and clinical trials run on USD pricing. Major CROs (IQVIA, Labcorp, Parexel, PPD) price US trial activity in USD. A UK biotech running a Phase 2 trial with a US arm pays USD for the US-based investigator sites, US-based central lab work, and US regulatory consultants.
The structural asymmetry: revenue lands in USD across milestone events that may be years apart and individually worth millions; costs run continuously in GBP (UK head office, UK staff) and EUR (EU contract manufacturing, EMA regulatory). The forward contract is the primary tool for converting USD revenue uncertainty into GBP budget certainty.
The four currency flows in UK pharma and biotech
| Flow | Typical currency | Timing characteristic | Optimal handling |
|---|---|---|---|
| US licensing upfront and milestone receipts | USD | Large, irregular — tied to FDA or commercial milestones, often years apart | Forward contracts booked at deal signing for projected milestone dates; long-dated forwards up to 24 months |
| Royalty income | USD | Quarterly recurring once product is commercial | Rolling 6–12 month forward strategy covering projected quarterly royalty stream |
| US contract research and clinical trial spend | USD (outflow) | Monthly to quarterly through trial life — 12 to 60 months total | Specialist GBP/USD spot or short-dated forwards on regular CRO payments; multi-currency USD account fed by milestone receipts |
| EU contract manufacturing and regulatory | EUR (outflow) | Monthly to quarterly through manufacturing scale-up and EMA submissions | Specialist GBP/EUR rates; forward contracts on dated regulatory milestone payments to EU CDMOs |
The natural hedge — using USD revenue to pay USD costs — is one of the most powerful structural tools available to UK pharma and biotech. A biotech receiving a $10 million USD milestone payment that also has $4 million of US-based CRO obligations across the next 12 months can hold the milestone USD in a multi-currency account and pay the CRO directly without ever converting through GBP. The 3 to 4 percent retail FX margin saved on $4 million is £100,000+, recovered straight to runway.
Licensing milestones: forward contracts for multi-year USD receipts
A typical US licensing deal for a clinical-stage UK biotech asset structures payments across 5 to 10 separate milestone events over 5 to 12 years:
- Upfront payment. $10 million to $200 million at signing depending on asset stage and indication. Paid within 30 to 60 days of deal close.
- Development milestones. $5 million to $50 million each at IND filing, Phase 2 start, Phase 3 start, NDA acceptance, FDA approval, EMA approval, additional indications. Spread across 3 to 8 years from signing.
- Commercial milestones. Triggered when product hits sales thresholds ($100m, $250m, $500m, $1bn annual sales). Variable timing.
- Royalty stream. Tiered percentage of net sales, recurring quarterly once commercial. Long tail of 10 to 20 years from launch.
The structural challenge: the GBP-equivalent value of each milestone depends on the GBP/USD rate on the payment date — which could be 6 months, 2 years, or 5 years from the deal signing. A 10 to 15 percent GBP/USD move across that horizon (well within historical norms) changes the GBP value of a $50 million milestone by £4 million to £6 million.
“For UK biotechs, the milestone forward strategy is not a finance team optimisation — it’s a runway-protection decision,” says Anthony Bull, CEO of Cambridge Currencies. “When a $30 million milestone might be worth £22 million one day and £25 million the next purely on currency movement, you’re effectively asking shareholders to bet runway months on FX timing. The forward contract is what turns a $30 million milestone into a known GBP number you can plan against.”
Forward contracts on milestone payments share characteristics with construction milestone forwards — covered in our UK construction overseas projects FX guide — but with two pharma-specific twists:
- Date uncertainty is larger. Clinical milestones can slip by months or years. Forward contracts need to be sized smaller and laddered more conservatively, with explicit roll provisions for date movement.
- Trigger uncertainty is real. Unlike construction milestones (which will happen, just with date risk), pharma milestones may never happen if the asset fails at a trial. Most UK biotechs hedge only a fraction of projected milestone value to limit downside if a milestone falls away.
Clinical trial and CRO USD outflows
The cost side of US-facing pharma activity is dominated by USD outflows to contract research organisations, central laboratories, US investigator sites, US regulatory consultants and Delaware-based legal counsel. A Phase 2 trial with a US arm typically runs $20 million to $60 million in USD cost across 24 to 36 months; a Phase 3 trial can run $100 million to $300 million.
The optimal handling depends on whether the UK biotech also has USD revenue:
- Biotechs with USD revenue (post-licensing). Hold milestone USD in a multi-currency account; pay CRO and other USD costs directly from that account. Natural hedge — no conversion needed, no margin lost. The full mechanics for handling USD invoices from the UK side are in our paying USD invoices from UK guide.
- Pre-revenue clinical-stage biotechs. All USD outflows convert from GBP funding (equity raises, grants, EIS/SEIS proceeds). Specialist GBP/USD rates at 0.4 to 0.6 percent margin versus UK bank retail at 3 to 4 percent represents £80,000 to £100,000+ per $5 million of CRO spend. On a $50 million Phase 3 trial, the cumulative saving from specialist routing is £1 million+.
- Forward contracts on dated CRO obligations. Once a CRO contract is signed with defined milestone payment schedule, forward contracts can lock the GBP cost of each scheduled payment. Useful for budget certainty when reporting trial costs to the board or investors.
Worked example: clinical-stage UK biotech with $30m USD licensing deal
A representative clinical-stage UK biotech that has just signed a US licensing deal: $10 million upfront, $20 million in development milestones across 4 years, mid-single-digit royalties on eventual sales. The biotech also runs $4 million of US-based Phase 2 trial spend across the next 18 months:
| Flow | USD value | Default approach | Specialist strategy | Saving |
|---|---|---|---|---|
| $10m upfront receipt | $10,000,000 | UK bank GBP/USD conversion at 3.5% = £258,000 lost on ~£7.4m equivalent | Specialist 0.5% spot + hold portion as USD for trial spend = £37,000 cost | £221,000 |
| $20m development milestones (4-year horizon) | $20,000,000 | Spot at each receipt; cumulative spot risk ~10–15% across horizon = £1.5m–£2.2m GBP equivalent swing | Laddered forwards at deal signing locking ~50–70% of projected GBP equivalent; saves 0.5% per milestone + eliminates spot swing | £100,000+ in margin saved + GBP-equivalent budget certainty |
| $4m US CRO trial spend (18 months) | $4,000,000 outflow | UK bank GBP→USD on each invoice at 3.5% = £105,000 lost | Pay directly from upfront USD held in multi-currency account; zero conversion cost | £105,000 |
| Total identified saving | £1.86m–£2.56m cost + exposure | £37,000 cost; ~£100k+ on milestones; £0 on CRO | £426,000+ saved + ~£2m volatility eliminated |
The combined improvement on a deal of this size is material to the biotech’s GBP runway. £426,000+ of FX margin saved is approximately 3 to 6 months of runway for a typical clinical-stage UK biotech burning £80,000 to £150,000 a month. The volatility elimination — knowing what each milestone will be worth in GBP terms — is at least as valuable for board reporting and investor communication.
M&A and acquisition FX for UK pharma
UK pharma M&A — either as acquirer of US assets or as target of US acquirers — carries large discrete USD flows that benefit from explicit FX strategy:
- UK pharma acquiring a US asset. The deal currency is USD; the UK acquirer’s working capital is GBP. A deal-contingent forward booked at signing can lock the GBP cost of the acquisition at the announced rate, removing GBP/USD risk between announcement and close (typically 3 to 9 months).
- UK biotech being acquired by a US buyer. Upfront cash typically USD, with milestone-based contingent value rights (CVRs) often extending years post-close. Multiple discrete forward contracts can hedge each payment date independently.
- Earn-out and CVR structures. Common in UK biotech M&A. CVRs paid 2 to 7 years post-close on milestone achievement carry the same FX risk profile as licensing milestones — laddered forwards or partial hedge depending on confidence in milestone delivery.
The detail on selecting the right broker for these high-value, complex flows sits in our UK business currency broker guide. Counterparty diversification considerations — material given typical transaction sizes — are covered in our single FX provider risk guide.
Common mistakes UK pharma and biotech finance teams make
- Converting USD milestone receipts immediately to GBP at UK bank rates. A $10 million milestone converted at UK bank retail margin of 3.5 percent costs £258,000 in unnecessary FX margin. Specialist routing recovers most of this.
- Not using USD revenue to pay USD costs. A biotech receiving USD milestones while paying USD CROs from GBP funding pays the FX margin twice on the same money — once converting USD→GBP at receipt, once converting GBP→USD at supplier payment. Multi-currency accounts eliminate this entirely.
- No forward strategy on multi-year licensing milestones. Reporting USD-denominated milestones at “today’s rate” implies stability that doesn’t exist. Forward contracts booked at deal signing turn projected GBP values into committed GBP values.
- Hedging 100 percent of projected milestone value. Pharma milestones can be triggered late, partially or not at all. Over-hedging creates exposure if the milestone doesn’t deliver. Most UK biotechs hedge 50 to 70 percent of projected milestone value, leaving headroom for delivery risk.
- Ignoring EU manufacturing FX. While USD revenue dominates the conversation, EU CDMO contracts in EUR can run £5 million to £30 million across a manufacturing campaign. GBP/EUR exposure on these contracts deserves the same forward-contract treatment as USD revenue — detail in our paying EUR bills from the UK guide.
- Single-counterparty concentration on large milestone receipts. Receiving a $50 million milestone into one bank or fintech account concentrates counterparty risk. Splitting across an FCA-authorised payment institution plus a banking relationship provides redundancy at no additional FX cost.
Speak to a specialist about your pharma or biotech FX
If you’re a UK pharma or biotech CFO, finance director or commercial lead with USD revenue from US licensing, partnerships or contract research, a short conversation with a Cambridge Currencies specialist will set out how multi-currency milestone receipt, laddered forward contracts, and natural USD-revenue/USD-cost hedging apply to your specific deal structure. Every transaction is completed by phone with a dedicated specialist who knows your milestone schedule and project timeline. The pillar reference for UK business FX is our UK business foreign exchange guide; for parallel sectoral approaches, see our UK oil & gas currency exchange guide and UK construction overseas projects FX guide.
Related guides in our business FX cluster
- UK business foreign exchange — the comprehensive pillar guide
- UK oil & gas currency exchange — parallel sectoral FX template
- UK construction overseas projects FX — milestone forward strategy
- UK business forward contracts — rate-locking mechanics for dated payments
- Paying USD invoices from the UK — USD outflow mechanics
- Receiving international payments — multi-currency receipt structure
- How to choose a UK business currency broker — broker selection framework
Sources: Association of the British Pharmaceutical Industry, UK Office for Life Sciences, FCA Financial Services Register.
